Winston & Strawn

Site Search

Professionals (98)
Capabilities (39)
Experience (86)
Insights & News (2,804)
Other Results (45)

Professionals 98 results

Emilie Woodhead

Of Counsel

Los Angeles

+1 213-615-1823

vCard

Of Counsel

Los Angeles

Winston Hu

Associate

Los Angeles

+1 213-615-1738

vCard

Associate

Los Angeles

Joan Fife

Partner

San Francisco

+1 415-591-1513

vCard

Partner

San Francisco

View All Professionals

Capabilities 39 results

Practice Area

Corporate Governance

Our attorneys have extensive experience counseling U.S. and multinational public companies across a range of industries in all aspects of corporate governance, securities, and compliance matters. We advise public companies, boards of directors and their committees, and senior executives on the corporate governance and compliance matters that public companies and their leadership confront—from board structuring and succession planning to shareholder activism and SEC regulation. Drawing on our experience as seasoned counselors, we keep clients abreast of evolving trends and best practices to proactively manage any governance or compliance issues. We have assembled one of the most experienced teams of any law firm in the country that’s counseling public companies....Read more

Practice Area

Labor & Employment

Our Labor & Employment Practice is one of the largest and most experienced practices among the country’s multi-disciplined law firms. Our attorneys represent global employers of all types and sizes—ranging from the Fortune 100 to privately held startups—often serving as national, regional, or preferred counsel to many of these major employers....Read more

Practice Area

ERISA Litigation

As a firm of choice for many major businesses, we represent employers, fiduciaries, boards of directors, benefit plans, and plan administrators in all aspects of ERISA litigation, including claims relating to fiduciary liability, plan investments, excessive fees, plan qualification, plan termination, reversion of excess assets, retiree medical benefits, severance and employment contract matters, tax liability matters, and retirement and welfare benefit claims....Read more

Experience 86 results

Experience

August 19, 2025

Winston Advised Ellipsis Onshore Holdings in the Acquisition of Oil and Gas Non-Operated Assets in the Permian Basin of Texas and New Mexico

Winston advised Ellipsis U.S. Onshore Holdings LLC, a portfolio company of the Westlawn Group, in connection with the acquisition of high-quality, non-operated working interests in the Permian Basin of Texas and New Mexico—adding approximately 4,000 barrels of oil equivalent per day in net production and over 600 gross remaining drilling locations. This strategic transaction strengthens Ellipsis’ Delaware Basin footprint and supports its strategy of scaling through high-margin, low-cost assets....Read more

Experience

July 15, 2025

Atsion Commits Up to $200 Million in Strategic OFA Investment

Winston & Strawn is representing Atsion Opportunity Fund LLC – Series 1 in connection with its committed equity facility of up to US$200M with OFA Group. The facility enables OFA to issue and sell ordinary shares over a 36-month period to support its cryptocurrency treasury strategy....Read more

Experience

April 23, 2025

Voyager Acquisition Corp. and VERAXA Biotech Announce Business Combination

Winston & Strawn represented Voyager Acquisition Corp. in its announced business combination agreement with VERAXA Biotech AG, a biopharmaceutical company developing next-generation antibody-based cancer therapies. The combination will result in VERAXA becoming a publicly traded company on Nasdaq under the ticker symbol “VERX”, with a pre-money equity valuation of $1.3 billion and up to $253 million in cash held in trust by Voyager. The transaction is expected to close in the fourth quarter of 2025, subject to regulatory and shareholder approvals....Read more

View All Experience

Insights & News 2,804 results

Webinar

September 18, 2025

U.S.–Brazil Trade Policy and Relations: Sanctions, Bilateral Agreements & 2025 Outlook

Please join us for a timely webinar discussing the evolving landscape of U.S.–Brazil trade relations, featuring experts across the private sector and public authorities in Brazil and the United States....Read more

Investigations, Enforcement, & Compliance Alerts

September 10, 2025

4 Min Read

DoD Publishes Final Cybersecurity Maturity Model Certification Rule

On September 10, 2025, the Department of Defense (DoD) published its long-awaited final DFARS rule on the Cybersecurity Maturity Model Certification (CMMC) Program.

Direct Sellers Update: Regulation, Law & Policy

September 9, 2025

3 Min Read

No More Click to Cancel Rule—But FTC Enforcement Actions Keep Coming

The FTC’s much-anticipated “Click to Cancel” Rule was nixed, but the FTC is not backing down. The FTC continues to use Section 5 of the FTC Act and various other regulations to bring enforcement actions against companies that fail to provide clear and conspicuous disclosures about recurring charges and easy-to-cancel options for consumers.

View All Insights & News

Other Results 45 results

Site Content

What Is an IPO Quiet Period?

A quiet period, also known as as the ‘pre-filing period,’ is the period that begins on the date an offering commences (often the date that Company retains an investment bank) and ends upon the public filing of the registration statement. It is referred to as the quiet period because of the SEC’s restrictions on publicity about the company and/or promoting its offering....Read more

Site Content

What Is the Cooling-Off Period for an IPO?

The cooling-off period is the period of time between the public filing of a registration statement with the SEC and the date the registration statement becomes effective. During this period, no sales may take place. Written offers may only be made with a prospectus meeting the requirements of Section 10 of the Securities Act. Certain oral offers including roadshow presentations may occur during this time along with testing the waters (TTW) activities with certain potential investors. ...Read more

Law Glossary

What Exclusivity Periods Are Associated with Biosimilars?

An applicant may not submit an aBLA until four years after the reference product is licensed by the FDA. (See BPCIA § 351(k).) Further, any biosimilar licenses “may not be made effective” until 12 years after the reference product was licensed. (See BPCIA § 351(l).)...Read more